Thongprayoon Charat, Cheungpasitporn Wisit, Gillaspie Erin A, Greason Kevin L, Kashani Kianoush B
Charat Thongprayoon, Wisit Cheungpasitporn, Kianoush B Kashani, Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States.
World J Nephrol. 2016 Sep 6;5(5):482-8. doi: 10.5527/wjn.v5.i5.482.
To assess red blood cell (RBC) transfusion effects on acute kidney injury (AKI) after transcatheter aortic valve replacement (TAVR).
A literature search was performed using MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and clinicaltrials.gov from the inception of the databases through December 2015. Studies that reported relative risk, odds ratio or hazard ratio comparing the risks of AKI following TAVR in patients who received periprocedural RBC transfusion were included. Pooled risk ratio (RR) and 95%CI were calculated using a random-effect, generic inverse variance method.
Sixteen cohort studies with 4690 patients were included in the analyses to assess the risk of AKI after TAVR in patients who received a periprocedural RBC transfusion. The pooled RR of AKI after TAVR in patients who received a periprocedural RBC transfusion was 1.95 (95%CI: 1.56-2.43) when compared with the patients who did not receive a RBC transfusion. The meta-analysis was then limited to only studies with adjusted analysis for confounders assessing the risk of AKI after TAVR; the pooled RR of AKI in patients who received periprocedural RBC transfusion was 1.85 (95%CI: 1.29-2.67).
Our meta-analysis demonstrates an association between periprocedural RBC transfusion and a higher risk of AKI after TAVR. Future studies are required to assess the risks of severe AKI after TAVR requiring renal replacement therapy and mortality in the patients who received periprocedural RBC transfusion.
评估红细胞(RBC)输注对经导管主动脉瓣置换术(TAVR)后急性肾损伤(AKI)的影响。
通过检索MEDLINE、EMBASE、Cochrane系统评价数据库和clinicaltrials.gov,纳入自建库起至2015年12月报道围手术期接受RBC输注的患者TAVR术后AKI风险并比较相对危险度、比值比或风险比的研究。采用随机效应、通用逆方差法计算合并风险比(RR)及95%可信区间(CI)。
16项队列研究共4690例患者纳入分析,以评估围手术期接受RBC输注的患者TAVR术后AKI风险。与未接受RBC输注的患者相比,围手术期接受RBC输注的患者TAVR术后AKI的合并RR为1.95(95%CI:1.56 - 2.43)。然后将荟萃分析仅限于对TAVR术后AKI风险进行混杂因素校正分析的研究;围手术期接受RBC输注的患者AKI的合并RR为1.85(95%CI:1.29 - 2.67)。
我们的荟萃分析表明围手术期RBC输注与TAVR术后较高的AKI风险相关。未来需要进一步研究评估围手术期接受RBC输注的患者TAVR术后需要肾脏替代治疗的严重AKI风险及死亡率。